Noven is based in Miami, Florida, but in 2009, the firm was acquired by Hisamitsu Pharmaceuticals in Japan, which is the world’s largest manufacturer of transdermal patches. Today, Noven serves as Hisamitsu’s platform for US prescription pharmaceuticals and is involved in both the development and manufacture of transdermal patches.
The company’s successes? The Vivelle-Dot estrogen patch and its successor, Minivelle – the world’s smallest estrogen patch; the first two-drug combination transdermal product to be released onto the market – CombiPatch; and the only marketed transdermal patch for ADHD (Daytrana). The patches utilize Noven’s ‘DOT Matrix’ technology, which is a class of diffusion-based drug-in-adhesive patch technologies. We connected with Noven via Jeff Mihm (CEO), Joel Lippman (Executive VP and Chief Medical Officer), Steven Dinh (VP and Chief Scientific Officer), and Patrick Gallagher (VP of Business Development) to find out more.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
